ArticleCureus2025
Questionnaire Survey on Enterococcus faecalis-2001 Supplementation in 137 Patients With Oral Diseases at Two Facilities.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLactic acid bacteria are gaining attention not only for their role in regulating the intestinal flora but also for their immunostimulatory effects. Recent clinical trials and in vitro studies have demonstrated the efficacy of heat-killed
methodsA prospective observational questionnaire-based study was conducted on 137 patients who had used granules or paste containing 7.5×10¹¹ EF-2001. Data were collected from November 2020 to March 2021 and from July 2021 to August 2024 at two different facilities.
resultsAt facility one (n=38), oral diseases included xerostomia (n=10, 26%), glossitis (n=8, 21%), stomatitis (n=7, 18%), oral candidiasis (n=5, 13%), and oral lichen planus (n=5, 13%). Ten patients were receiving cancer treatment or undergoing perioperative oral care. Intestinal symptoms were reported in 34 patients, mainly constipation (n=27, 71%) and diarrhea (n=7, 18%). Improvement in oral symptoms and intestinal symptoms was observed in 25 of 35 respondents (71%) and 18 of 31 (58%), respectively. The most common time-to-symptom improvement was two to four weeks. A significant association was found between improvements in oral and intestinal symptoms. At facility two (n=99), oral diseases included oral lichen planus (OLP) (n=49, 49%), glossodynia (n=12, 12%), oral candidiasis (n=10, 10%), pemphigus vulgaris (n=6, 6%), and Sjögren's syndrome (n=6, 6%). Intestinal symptoms were reported in 67 patients, mainly constipation (n=51, 52%) and diarrhea (n=16, 16%). Improvement in oral symptoms was reported in 64 of 98 respondents (65%), and in intestinal symptoms in 42 of 65 (65%). The most frequent time-to-improvement was two to four weeks for oral symptoms and four to eight weeks for intestinal symptoms. A significant association was again observed between improvements in oral and intestinal symptoms.
conclusionSupplementation with EF-2001 resulted in subjective improvements in both oral and intestinal symptoms across various oral diseases, with a notable association between the two types of symptom improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.